A lower eGFR_{cystatin C}/eGFR_creatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus

References

• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the international diabetes federation diabetes atlas, 9 edition. Diabetes Res Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843.
   PubMed Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17(1):83. doi: 10.1186/s12933-018-0728-6.
   PubMed Web of Science ®Google Scholar
• Morrish NJ, Wang SL, Stevens LK, et al. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44 Suppl 2(S2):S14–S21. doi: 10.1007/pl00002934.
   PubMedGoogle Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Grubb A, Lindström V, Jonsson M, et al. Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: ‘Shrunken pore syndrome. Scand J Clin Lab Invest. 2015;75(4):333–340. doi: 10.3109/00365513.2015.1025427.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–S9. doi: 10.1053/ajkd.1998.v32.pm9820470.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049–2060. doi: 10.1056/NEJMoa043161.
   PubMed Web of Science ®Google Scholar
• Schöttker B, Herder C, Müller H, et al. Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes. Diabetes Care. 2012;35(4):879–886. doi: 10.2337/dc11-1998.
   PubMed Web of Science ®Google Scholar
• Grubb A. Shrunken pore syndrome - a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options. Clin Biochem. 2020;83:12–20. doi: 10.1016/j.clinbiochem.2020.06.002.
   PubMed Web of Science ®Google Scholar
• Larsson AO, Hultström M, Frithiof R, et al. Shrunken pore syndrome is frequently occurring in severe COVID-19. Int J Mol Sci. 2022;23(24):15687. doi: 10.3390/ijms232415687.
   PubMed Web of Science ®Google Scholar
• Almén MS, Björk J, Nyman U, et al. Shrunken pore syndrome is associated with increased levels of atherosclerosis-Promoting proteins. Kidney Int Rep. 2019;4(1):67–79. doi: 10.1016/j.ekir.2018.09.002.
   PubMed Web of Science ®Google Scholar
• Zhang LW, Luo MQ, Xie XW, et al. Shrunken pore syndrome: a new and more powerful phenotype of renal dysfunction than chronic kidney disease for predicting Contrast-Associated acute kidney injury. J Am Heart Assoc. 2023;12:e027980.
   PubMed Web of Science ®Google Scholar
• Xhakollari L, Grubb A, Jujic A, et al. The shrunken pore syndrome is associated with poor prognosis and lower quality of life in heart failure patients: the HARVEST-Malmö study. ESC Heart Fail. 2021;8(5):3577–3586. doi: 10.1002/ehf2.13485.
   PubMed Web of Science ®Google Scholar
• Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20–29. doi: 10.1056/NEJMoa1114248.
   PubMed Web of Science ®Google Scholar
• Jin B, Bai X, Han L, et al. Association between kidney function and framingham global cardiovascular disease risk score: a chinese longitudinal study. PLoS One. 2014;9(1):e86082. doi: 10.1371/journal.pone.0086082.
   PubMed Web of Science ®Google Scholar
• Lee K, Kim J. Estimated glomerular filtration rate and albuminuria in korean population evaluated for cardiovascular risk. Int Urol Nephrol. 2016;48(5):759–764. doi: 10.1007/s11255-016-1244-9.
   PubMed Web of Science ®Google Scholar
• Bai X, Han L, Liu J, et al. The relationship between age-related kidney dysfunction and framingham risk score in healthy people in China. Curr Aging Sci. 2010;3(3):188–197. doi: 10.2174/1874609811003030188.
   PubMedGoogle Scholar
• Khaloo P, Alemi H, Mansournia MA, et al. Loss of inverse association between framingham risk score and estimated glomerular filtration rate in moderate to severe diabetic kidney disease. Arch Iran Med. 2019;22:91–98.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–525. doi: 10.1016/S2213-8587(15)00040-6.
   PubMed Web of Science ®Google Scholar
• Chang A, Kramer H. Should eGFR and albuminuria be added to the framingham risk score? Chronic kidney disease and cardiovascular disease risk prediction. Nephron Clin Pract. 2011;119(2):c171–c178. discussion c177-8. doi: 10.1159/000325669.
   PubMedGoogle Scholar
• Stevens LA, Zhang Y, Schmid CH. Evaluating the performance of equations for estimating glomerular filtration rate. J Nephrol. 2008;21(6):797–807.
   PubMed Web of Science ®Google Scholar
• Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38(10):1933–1953.
   PubMed Web of Science ®Google Scholar
• Yoo J-J, Kim SG, Kim YS, et al. Estimation of renal function in patients with liver cirrhosis: impact of muscle mass and sex. J Hepatol. 2019;70(5):847–854. doi: 10.1016/j.jhep.2018.12.030.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Inker LA, Coresh J. Serum cystatin C for estimation of GFR. JAMA. 2022;328(9):883–884. doi: 10.1001/jama.2022.12407.
   PubMed Web of Science ®Google Scholar
• Grubb A, Björk J, Nyman U, et al. Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand J Clin Lab Invest. 2011;71(2):145–149. doi: 10.3109/00365513.2010.546879.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang S, Huo X, et al. Cystatin C expression is promoted by VEGFA blocking. With Inhibitory Effects on Endothelial Cell Angiogenic Functions Including Proliferation, Migration, and Chorioallantoic Membrane Angiogenesis. J Am Heart Assoc. 2018;7:e009167.
   Google Scholar
• Öberg CM, Lindström M, Grubb A, et al. Potential relationship between eGFRcystatin C/eGFRcreatinine-ratio and glomerular basement membrane thickness in diabetic kidney disease. Physiol Rep. 2021;9:e14939.
   PubMed Web of Science ®Google Scholar
• Herou E, Dardashti A, Nozohoor S, et al. The mortality increase in cardiac surgery patients associated with shrunken pore syndrome correlates with the eGFRcystatin C/eGFRcreatinine-ratio. Scand J Clin Lab Invest. 2019;79(3):167–173. doi: 10.1080/00365513.2019.1576101.
   PubMed Web of Science ®Google Scholar
• Åkesson A, Lindström V, Nyman U, et al. Shrunken pore syndrome and mortality: a cohort study of patients with measured GFR and known comorbidities. Scand J Clin Lab Invest. 2020;80(5):412–422. doi: 10.1080/00365513.2020.1759139.
   PubMed Web of Science ®Google Scholar
• Dardashti A, Nozohoor S, Grubb A, et al. Shrunken pore syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting. Scand J Clin Lab Invest. 2016;76(1):74–81. doi: 10.3109/00365513.2015.1099724.
   PubMed Web of Science ®Google Scholar